A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 72 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.
Among the 24 studies testing zenagamtide in Obesity, this one is the 8th largest by enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 2 of the 19 other live ones, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 19 started in 2026.
This study's enrollment of 606 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 360 across the 24 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 27th largest by enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 41 of the 65 other live ones, and was the 168th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing zenagamtide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous injection of NNC0487-0111 once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
Participants will receive subcutaneous injection of placebo matched to NNC0487-0111 once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Placebo (matched to NNC0487-0111)
NNC0487-0111 will be administered subcutaneously.
Placebo will be administered subcutaneously.
Relative change in body weight
Measured as percentage (%) of body weight.
Time frame: From week 40 to week 92
Relative change in body weight
Measured as % of body weight.
Time frame: From week 0 to week 92
Change in waist circumference
Measured as centimetre (cm).
Time frame: From week 40 to week 92
Change in systolic blood pressure (SBP)
Measured as millimeter of mercury (mmHg).
Time frame: From week 40 to week 92
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.
Time frame: From week 40 to week 92
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score
Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate better functional health and well-being. The physical functioning ranges from 19.0 to 57.6.
Time frame: From week 40 to week 92
Change in body weight
Measured as kilogram (kg).
Time frame: From week 40 to week 92
Change in body mass index (BMI)
Measured as kilograms per square meter (kg/m\^2).
Time frame: From week 40 to week 92
Change in body weight
Measured as kg.
Time frame: From week 0 to week 92
Change in BMI
Measured as kg/m\^2.
Time frame: From week 0 to week 92
Change in glycated haemoglobin (HbA1c)
Measured as % of HbA1c.
Time frame: From week 40 to week 92
Change in fasting plasma glucose (FPG)
Measured as millimoles per liter (mmol/L).
Time frame: From week 40 to week 92
Change in fasting insulin
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in diastolic blood pressure (DBP)
Measured as mmHg.
Time frame: From week 40 to week 92
Change in total cholesterol
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in High-density lipoprotein (HDL) cholesterol
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in Low-density lipoprotein (LDL) cholesterol
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in Very low-density lipoprotein (VLDL) cholesterol
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in non-HDL cholesterol
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in triglycerides
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in high-sensitivity C-reactive protein (hsCRP)
Measured as ratio to baseline.
Time frame: From week 40 to week 92
Change in HbA1c
Measured as % of HbA1c.
Time frame: From week 0 to week 92
Change in FPG
Measured as mmol/L.
Time frame: From week 0 to week 92
Change in fasting insulin
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in DBP
Measured as mmHg.
Time frame: From week 0 to week 92
Change in total cholesterol
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in HDL cholesterol
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in LDL cholesterol
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in VLDL cholesterol
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in non-HDL cholesterol
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in triglycerides
Measured as ratio to baseline.
Time frame: From week 0 to week 92
Change in hsCRP
Measured as % of hsCRP.
Time frame: From week 0 to week 92
Change in waist circumference
Measured as cm.
Time frame: From week 0 to week 92
Change in SBP
Measured as mmHg.
Time frame: From week 0 to week 92
Change in IWQOL-Lite-CT: physical composite score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical composite score ranges from 0-100.
Time frame: From week 40 to week 92
Change in IWQOL-Lite-CT: psychosocial composite score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The psychosocial composite score ranges from 0-100.
Time frame: From week 40 to week 92
Change in IWQOL-Lite-CT: total score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.
Time frame: From week 40 to week 92
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as events.
Time frame: From week 0 to week 40
Number of Treatment Emergent Serious Adverse Events (TESAEs)
Measured as events.
Time frame: From week 0 to week 40
Number of TEAEs leading to permanent treatment discontinuation
Measured as events.
Time frame: From week 0 to week 40
Number of TEAEs
Measured as events.
Time frame: From week 40 to week 96
Number of TESAEs
Measured as events.
Time frame: From week 40 to week 96
Number of TEAEs leading to permanent treatment discontinuation
Measured as events.
Time frame: From week 40 to week 96
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 25 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide